Wellington Management Group LLP Purchases 260,494 Shares of Integra LifeSciences Holdings Corporation (IART)

Wellington Management Group LLP raised its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 98.9% during the first quarter, Holdings Channel reports. The firm owned 523,921 shares of the life sciences company’s stock after buying an additional 260,494 shares during the period. Wellington Management Group LLP’s holdings in Integra LifeSciences Holdings Corporation were worth $22,073,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in IART. Principal Financial Group Inc. boosted its stake in Integra LifeSciences Holdings Corporation by 107.1% in the first quarter. Principal Financial Group Inc. now owns 468,680 shares of the life sciences company’s stock worth $19,746,000 after buying an additional 242,340 shares during the period. OppenheimerFunds Inc. boosted its position in shares of Integra LifeSciences Holdings Corporation by 54.1% in the first quarter. OppenheimerFunds Inc. now owns 464,999 shares of the life sciences company’s stock valued at $19,591,000 after buying an additional 163,212 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Integra LifeSciences Holdings Corporation by 102.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 13,670 shares of the life sciences company’s stock valued at $576,000 after buying an additional 6,910 shares during the last quarter. Burney Co. boosted its position in shares of Integra LifeSciences Holdings Corporation by 100.0% in the first quarter. Burney Co. now owns 5,810 shares of the life sciences company’s stock valued at $245,000 after buying an additional 2,905 shares during the last quarter. Finally, Tributary Capital Management LLC boosted its position in shares of Integra LifeSciences Holdings Corporation by 148.6% in the first quarter. Tributary Capital Management LLC now owns 408,960 shares of the life sciences company’s stock valued at $17,229,000 after buying an additional 244,483 shares during the last quarter. Institutional investors own 89.74% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at 53.97 on Tuesday. Integra LifeSciences Holdings Corporation has a 12-month low of $37.38 and a 12-month high of $54.68. The company’s 50-day moving average price is $49.31 and its 200 day moving average price is $50.27. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of 64.25 and a beta of 0.76.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.40 by $0.01. Integra LifeSciences Holdings Corporation had a net margin of 6.66% and a return on equity of 16.67%. The firm had revenue of $258.60 million during the quarter, compared to analysts’ expectations of $254.19 million. During the same period in the previous year, the firm posted $0.38 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. On average, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post $1.92 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Wellington Management Group LLP Purchases 260,494 Shares of Integra LifeSciences Holdings Corporation (IART)” was published by sleekmoney and is the property of of sleekmoney. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://sleekmoney.com/wellington-management-group-llp-purchases-260494-shares-of-integra-lifesciences-holdings-corporation-iart/1942653.html.

Several research analysts have recently issued reports on IART shares. Piper Jaffray Companies restated an “overweight” rating and issued a $47.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, March 22nd. ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC raised their price objective on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price objective on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research note on Monday, May 15th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $48.00 price objective (up from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, May 2nd. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $50.17.

In other Integra LifeSciences Holdings Corporation news, Director James M. Sullivan sold 15,658 shares of the company’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $45.89, for a total transaction of $718,545.62. Following the completion of the sale, the director now directly owns 70,154 shares of the company’s stock, valued at approximately $3,219,367.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Stuart Essig sold 140,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $48.01, for a total value of $6,721,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 304,523 shares of company stock valued at $14,812,988. 21.40% of the stock is owned by company insiders.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/wellington-management-group-llp-purchases-260494-shares-of-integra-lifesciences-holdings-corporation-iart/1942653.html

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *